Top entities: Regeneron Pharmaceuticals, Pomerantz LLP, Danielle Peyton.

What category does this event fall under?

Regulatory — classified as securities fraud investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Regulatory securities fraud investigation

Pomerantz investigates Regeneron Pharmaceuticals fraud

Q: When did this event occur?

First reported May 21, 2026; last updated Jun 02, 2026.

Q: What is the market impact?

General. The market is negatively impacted by the news of Regeneron Pharmaceuticals' failed Phase 3 trial, leading to a significant drop in its stock price.

Analysis based on 11 articles · First reported May 21, 2026 · Last updated Jun 02, 2026

Sentiment

-50

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is negatively impacted by the news of Regeneron Pharmaceuticals' failed Phase 3 trial, leading to a significant drop in its stock price. The subsequent investigation by Pomerantz LLP could result in further financial and reputational damage for Regeneron Pharmaceuticals.

Pharmaceuticals Legal Services

Event Summary

Pomerantz LLP is investigating Regeneron Pharmaceuticals, Inc. for alleged securities fraud and unlawful business practices. This investigation follows Regeneron's announcement on May 15, 2026, that its Phase 3 trial for fianlimab and cemiplimab as a first-line treatment for advanced melanoma did not achieve statistical significance for its primary endpoint. This news caused Regeneron's stock price to fall by 9.82% on May 16, 2026. Pomerantz LLP is encouraging affected investors to contact Danielle Peyton to join the potential class action lawsuit.

Entities Involved

stock

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is under investigation for potential securities fraud and unlawful business practices after its stock price fell significantly due to disappointing Phase 3 trial results for its melanoma treatment.

Importance 100.0 Sentiment -70.0

priv

Pomerantz LLP

Pomerantz LLP is a law firm investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. for alleged securities fraud, aiming to recover damages for class members.

Importance 80.0 Sentiment 20.0

per

Danielle Peyton

Danielle Peyton is a contact person at Pomerantz LLP for investors interested in joining the class action against Regeneron Pharmaceuticals.

Importance 20.0 Sentiment 0.0

Relationships

Pomerantz LLP related ↔ Danielle Peyton

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard